Immunic任命资深生物制药高管Michael A. Panzara博士担任首席医疗官

美股速递04-28 18:32

生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士（Michael A. Panzara, M.D., M.P.H.）担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。

潘扎拉博士曾主导多项重大临床项目，并在神经科学、免疫学等治疗领域取得显著成果。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。

这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。公司表示，潘扎拉博士的行业经验和科学洞察将为其治疗自身免疫性疾病和炎症性疾病的创新疗法开发提供重要支撑。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1184465464?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-28 18:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184465464","market":"us","top_or_hot":-1,"title":"Immunic任命资深生物制药高管Michael A. Panzara博士担任首席医疗官","media":"美股速递","content":"<p>生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士（Michael A. Panzara, M.D., M.P.H.）担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。</p>\n<p>潘扎拉博士曾主导多项重大临床项目，并在神经科学、免疫学等治疗领域取得显著成果。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。</p>\n<p>这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。公司表示，潘扎拉博士的行业经验和科学洞察将为其治疗自身免疫性疾病和炎症性疾病的创新疗法开发提供重要支撑。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immunic任命资深生物制药高管Michael A. Panzara博士担任首席医疗官</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunic任命资深生物制药高管Michael A. Panzara博士担任首席医疗官\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-28 18:32 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士（Michael A. Panzara, M.D., M.P.H.）担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。\n潘扎拉博士曾主导多项重大临床项目，并在神经科学、免疫学等治疗领域取得显著成果。他的加入有望加速...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMUX","symbol_name":"Immunic, Inc.","start_time":0,"source_url":"","article_id":"1184465464","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184465464","pubTimestamp":1777372328,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IMUX":"Immunic, Inc.","BK4139":"生物科技"},"translate_title":"Immunic Appoints Veteran Biopharma Executive Dr. Michael A. Panzara as Chief Medical Officer","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMUX":1},"content_text":"生物医药公司Immunic, Inc.正式宣布，任命在生物制药领域拥有丰富经验的迈克尔·A·潘扎拉博士（Michael A. Panzara, M.D., M.P.H.）担任首席医疗官一职。潘扎拉博士在药物研发和临床开发方面具备深厚资历，此次任命将强化Immunic在创新疗法开发领域的领导团队。\n潘扎拉博士曾主导多项重大临床项目，并在神经科学、免疫学等治疗领域取得显著成果。他的加入有望加速Immunic管线药物的临床推进，并为公司战略规划注入新的专业视角。\n这一人事变动彰显了Immunic持续加强研发实力、推进旗下候选药物全球开发的决心。公司表示，潘扎拉博士的行业经验和科学洞察将为其治疗自身免疫性疾病和炎症性疾病的创新疗法开发提供重要支撑。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184465464","isCrawlerRequest":true}